
PBH Stock Forecast & Price Target
PBH Analyst Ratings
Bulls say
Prestige Consumer is well-positioned for growth and has a diverse portfolio of leading brands in niche consumer health categories, giving it a competitive edge. The company has a solid track record of generating positive annual free cash flow, with a commitment to reaching <3.0x net debt/adjusted EBITDA by early to mid-2027. While there are potential risks, such as commodity inflation and uncertainties around non-core asset monetizations, Prestige has a strong business model and potential for continued success.
Bears say
Prestige Consumer is facing headwinds in its main market, North America, as it faces increasing competition and pricing pressures. While its portfolio of leading brands in niche categories and recommendations from medical professionals may provide some stability, the company is still heavily reliant on a single geographic region. In addition, its recent acquisition of Clear Eyes may have limited potential for growth. The company's margin expansion is also expected to be slow, and it may face challenges in managing inflation and tariffs in the food production supply chain. The lack of diversity in its executive team is also a concern.
This aggregate rating is based on analysts' research of Prestige Brands Holdings and is not a guaranteed prediction by Public.com or investment advice.
PBH Analyst Forecast & Price Prediction
Start investing in PBH
Order type
Buy in
Order amount
Est. shares
0 shares